Back to drug list

Renflexis (infliximab-abda)


Billing

Code: Q5104

Description: Injection, renflexis

Unit: 10 mg

Payment: $32.562

Pay quarter: Q4 2023


Medicare history

Dosage and Frequency

Crohn's Disease (CD)
Ulcerative Colitis (UC)
Ankylosing Spondylitis (AS)
Psoriatic Arthritis (PsA)
Plaque Psoriasis (Ps)

Induction:
• 5mg/kg IV at 0, 2, and 6 weeks

Maintenance:
• 5mg/kg IV every 8 weeks

Rheumatoid Arthritis (RA)

Induction:
• 3mg/kg IV at 0, 2, and 6 weeks

Maintenance:
• 3mg/kg IV every 8 weeks

Calculate drug reimbursement


Total Reimbursement:

$976.86

(ASP: $921.57, Margin: $55.29)


Code:

Q5104

# Units to bill:

30

Prior Authorization

Prior auth criteria for Renflexis may include but is not limited to:


1. The patient must have a diagnosis of Rheumatoid Arthritis, Ankylosing Spondylitis, or Psoriatic Arthritis that is documented in the medical record.

2. The patient must have had an inadequate response to at least one TNF inhibitor therapy.

3. The patient must have an established diagnosis of moderate to severe chronic inflammatory arthritis for at least 6 months.

4. The patient must be 18 years of age or older.

5. The patient must have a body mass index (BMI) of less than 40 kg/m2.

6. The patient must have normal liver function tests.

7. The patient must have had a negative pregnancy test (in women of childbearing potential).

8. The patient must not have any active infections.

9. The patient must not have any other serious medical conditions that may increase the risk of Renflexis.


Insurance prior auth guidelines:

Aetna

United Healthcare

Anthem

Cigna


Billable NDCs

00006-4305-02

Renflexis (MERCK SHARP & DOHME CORP.)

100 MG


78206-0162-01

Renflexis (ORGANON LLC)

100 MG



Resources

Drug Enrollment Form

Website